Innate and adaptive immune responses in subjects with CPA secondary to post‐pulmonary tuberculosis lung abnormalities
Mycoses · 2024
DOI: 10.1111/myc.13746 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2024. Verfasst von Naresh Kumar Chirumamilla und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Adaptive Immunity, Immunity, Innate, Tuberculosis, Pulmonary, Pulmonary Aspergillosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background
Post‐tuberculosis lung abnormality (PTLA) is the most common risk factor for chronic pulmonary aspergillosis (CPA), and 14%–25% of the subjects with PTLA develop CPA. The pathogenesis and the host immune response in subjects with PTLA who develop CPA need to be better understood.
Methods
We prospectively compared the innate and adaptive immune responses mounted by patients of PTLA with or without CPA (controls). We studied the neutrophil oxidative burst (by dihydrorhodamine 123 test), classic (serum C3 and C4 levels) and alternative (mannose‐binding lectin [MBL] protein levels) complement pathway, serum immunoglobulins (IgG, IgM and IgA), B and T lymphocytes and their subsets in subjects with PTLA with or without CPA.
Results
We included 111 subjects (58 CPA and 53 controls) in the current study. The mean ± SD age of the study population was 42.6 ± 15.7 years. The cases and controls were matched for age, gender distribution and body weight. Subjects with CPA had impaired neutrophil oxidative burst, lower memory T lymphocytes and impaired Th‐1 immune response (lower Th‐1 lymphocytes) than controls. We found no significant difference between the two groups in the serum complement levels, MBL levels, B‐cell subsets and other T lymphocyte subsets.
Conclusion
Subjects with CPA secondary to PTLA have impaired neutrophil oxidative burst and a lower Th‐1 response than controls.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pediatric immunopathology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Doodhadhari Burfani Hospital, Haridwar, Uttarakhand, India.
- Department of Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
ORCID-Profile: Ritesh Agarwal, Valliappan Muthu, Shivaprakash M Rudramurthy, Arnab Pal, Inderpaul Singh Sehgal
Zitieren
APA
Chirumamilla, N. K., Arora, K., Kaur, M., Agarwal, R., Muthu, V., Rawat, A., Dhooria, S., Prasad, K. T., Aggarwal, A. N., Rudramurthy, S. M., Chakrabarti, A., Choudhary, H., Pal, A., & Sehgal, I. S. (2024). Innate and adaptive immune responses in subjects with CPA secondary to post‐pulmonary tuberculosis lung abnormalities. Mycoses. https://doi.org/10.1111/myc.13746
Vancouver
Chirumamilla NK, Arora K, Kaur M, Agarwal R, Muthu V, Rawat A, et al. Innate and adaptive immune responses in subjects with CPA secondary to post‐pulmonary tuberculosis lung abnormalities. Mycoses. 2024. doi:10.1111/myc.13746
BibTeX
@article{Chirumamilla2024,
author = {Chirumamilla, Naresh Kumar and Arora, Kanika and Kaur, Mandeep and Agarwal, Ritesh and Muthu, Valliappan and Rawat, Amit and Dhooria, Sahajal and Prasad, Kuruswamy Thurai and Aggarwal, Ashutosh Nath and Rudramurthy, Shivaprakash M and Chakrabarti, Arunaloke and Choudhary, Hansraj and Pal, Arnab and Sehgal, Inderpaul Singh},
title = {Innate and adaptive immune responses in subjects with CPA secondary to post‐pulmonary tuberculosis lung abnormalities},
journal = {Mycoses},
year = {2024},
doi = {10.1111/myc.13746}
}
EUVIMED